Advertisement

EnVivo Pharmaceuticals Inc. of Watertown, which focuses on central nervous system therapies, said it has started a Phase 1 trial of its EVP-0962 Alzheimer’s drug candidate in healthy volunteers.

The drug is a selective gamma secretase modulator that is being tested for safety, tolerability, pharmacokinetics, pharmacodynamics and food effects. The company said it has shown promising results in preclinical cellular and transgenic models, where genetic material has been transferred from one organism to another, of Alzheimer’s.

SOURCE

Advertisement
Advertisement